Main Article Content
COVID-19; serological evaluation; healthcare workers
Introduction: Severe Acquired Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) infection represents an unprecedented public health problem and, at present, vaccination is the only weapon available to combat the infection. The simplest and most immediate method to quantify the response of the subject's immune system to vaccination and / or infection is the serological assessment of the antibody titer. The objective of our study was 1) to evaluate the presence of antibody responses in a sample of healthcare workers subjected to a complete vaccination course as per ministerial provisions (double dose for negatives and single dose for ex-SARS-CoV subjects -2 positive) with Comirnaty vaccine (Pfizer / BioNTech) 2) evaluate the presence of statistically significant associations for sex, age and previous positive swab. Materials and methods: the antibody levels of both nucleocapsid antibodies and anti-Sars-CoV2 Spike antibodies of the study subjects were examined with the electrochemiluminescent immunoassay (ECLIA) method developed by Roche®. The cut-off value, as suggested by the manufacturer, for anti-nucleocapsid antibodies was 1 COI, while the Ig Spike value was 0.8 I / mL. The study sample was stratified by age (≤45 years, 46-55, ≥56 years old), previous positive molecular swab, gender and IgG S1 / S2 values at the completed vaccination course (≤200, ≥200 AU / mL ). Statistical analyzes were carried out with the R software. Results: almost all of the sample (89.45%) showed IgG Spike values> 200 AU / mL with statistically significant associations in relation to sex (greater in females, p≤0.05), to previous swab positivity in the presence of a vaccine dose (n = 44; p <0.001) and at age (with greater antibody response in subjects under 45; p <0.001). Discussion and conclusions: The current study confirms what is reported in the literature. In the light of the results obtained, it could be interesting to promote studies that evaluate the antibody titers trend over time a) in women of childbearing age and postmenopausal age b) in particular categories of subjects with chronic degenerative diseases to assess the actual need for doses booster, it being understood that the immune system response is guaranteed by both cellular and humoral immunity and that the antibody titer does not faithfully reflect the protection obtained.
4. Coronavirus disease (COVID-19) pandemic. Available on line on https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Last access 12.10.2020
5. COVID-19 pandemic. Available on line on https://www.ecdc.europa.eu/en/novel-coronavirus-china last access 12.10.2020
6. Hu, B., Guo, H., Zhou, P. et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19, 141–154 (2021). https://doi.org/10.1038/s41579-020-00459-7.
7. Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLoS One. 2021 May 3;16(5):e0250602. doi: 10.1371/journal.pone.0250602. PMID: 33939733; PMCID: PMC8092779.
8. Chen, Z., John Wherry, E. T cell responses in patients with COVID-19. Nat Rev Immunol 20, 529–536 (2020). https://doi.org/10.1038/s41577-020-0402-6
9. Dai, L., Gao, G.F. Viral targets for vaccines against COVID-19. Nat Rev Immunol 21, 73–82 (2021). https://doi.org/10.1038/s41577-020-00480-0
10. Wu, J., Liang, B., Chen, C. et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun 12, 1813 (2021). https://doi.org/10.1038/s41467-021-22034-1
11. European center of disease control . Immune responses and correlates of protective immunity against SARS-CoV-2. Available on https://www.ecdc.europa.eu/en/covid-19/latest-evidence/immune-responses#:~:text=Immune%20responses%20and%20correlates%20of,transmission%20risk%2C%20or%20disease%20outcome. Last access on 8 September 2021.
12. Summary of product characteristics. Comirnaty concentrate for injectable dispersion COVID-19 mRNA vaccine (nucleoside modified). Available on https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_005389_049269_RCP.pdf&retry=0&sys=m0b1l3
13. Amodio E, Capra G, Casuccio A, et al. Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients. Vaccines (Basel). 2021;9(7):714. Published 2021 Jul 1. doi:10.3390/vaccines9070714
14. The R Project for Statistical Computing (https://www.r-project.org/)
15. Zollner A, Watschinger C, Rössler A, Farcet MR, Penner A, Böhm V, Kiechl SJ, Stampfel G, Hintenberger R, Tilg H, Koch R, Antlanger M, Kreil TR, Kimpel J, Moschen AR. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. EBioMedicine. 2021 Aug;70:103539. doi: 10.1016/j.ebiom.2021.103539. Epub 2021 Aug 12. PMID: 34391087; PMCID: PMC8358275.
16. Klein, S.L.; Morgan, R. The impact of sex and gender on immunotherapy outcomes. Biol. Sex Differ. 2020, 11, 24.
17. Takahashi, T.; Ellingson, M.K.; Wong, P.; Israelow, B.; Lucas, C.; Klein, J.; Silva, J.; Mao, T.; Oh, J.E.; Tokuyama, M.; et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020, 588, 315–320.
18. Weisberg, S.P.; Connors, T.J.; Zhu, Y.; Baldwin, M.R.; Lin, W.-H.; Wontakal, S.; Szabo, P.A.; Wells, S.B.; Dogra, P.; Gray, J.; et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat. Immunol. 2020, 22, 25–31.
19. Westmeier J, Paniskaki K, Karaköse Z, Werner T, Sutter K, Dolff S, Overbeck M, Limmer A, Liu J, Zheng X, Brenner T, Berger MM, Witzke O, Trilling M, Lu M, Yang D, Babel N, Westhoff T, Dittmer U, Zelinskyy G. Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients. mBio. 2020 Sep 18;11(5):e02243-20. doi: 10.1128/mBio.02243-20. Erratum in: mBio. 2020 Nov 10;11(6): PMID: 32948688; PMCID: PMC7502863.